# Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer

> **NCT07645651** · PHASE1 · RECRUITING · sponsor: **University of Washington** · enrollment: 15 (estimated)

## Conditions studied

- Resectable Pancreatic Ductal Adenocarcinoma
- Borderline Resectable Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Samuraciclib
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Endoscopic Ultrasound Biopsy
- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT07645651
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-10-15
- **Primary completion:** 2027-07-14
- **Final completion:** 2027-11-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-09-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07645651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07645651, "Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07645651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*